Month: June 2025

Award-Winning DEXA Technology™ Continues to Redefine Patient-Matched Spinal Care Please click to view image CARLSBAD, CALIFORNIA, June 16, 2025 (GLOBE NEWSWIRE) — Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spinal implant technology, is proud to announce that its DEXA-C™ system has now been successfully used in more than 1,500 cervical spine procedures across the United States. This milestone underscores the ongoing adoption and trusted performance of the DEXA Technology™ platform, which was honored with the Best Technology in Spine Award. Aurora’s proprietary DEXA Technology™ is the world’s first spinal implant platform intentionally engineered to match a patient’s bone density across the entire BMD continuum, including normal, osteopenic,...

– Unveils Plans to Initiate Digital Asset Acquisition Strategy – – Enters LOI to Acquire Complementary Entity – – Realigns Corporate and North America Operations – SAN DIEGO, CA, June 16, 2025 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions leveraging electronic payment technology, has submitted a registration statement on Form S-1 with the Securities and Exchange Commission. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Additionally, management is executing strategic actions and enhancing its business plan:RYVYL isFocusing on growing its North America revenues, including pursuing a legacy vertical market, which at its peak, in the fourth quarter...

SAN DIEGO, CA, June 16, 2025 (GLOBE NEWSWIRE) — RYVYL Inc. (NASDAQ: RVYL) (“RYVYL” or the “Company”), a leading innovator of payment transaction solutions leveraging electronic payment technology, has appointed industry veteran Brett Moyer as an independent member of its board of directors, effective immediately. “I’m delighted to welcome Brett Moyer to our board,” said RYVYL Co-founder and Chairman Ben Errez. “Brett’s experience in building companies and proven expertise in scaling and licensing technology platforms will be instrumental as we focus on our next phase of growth opportunities. We look forward to his insights and leadership as we continue advancing our technology and expanding into new markets.” Moyer said, “I’m excited to join the RYVYL board during this transitional phase in the company’s history....

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025 Initial Phase 1 clinical data is expected in the first half of 2026 NextCure also gains rights to Simcere Zaiming’s proprietary linker and payload for use in an ADC directed to a NextCure novel target; Simcere Zaiming will have rights to greater ChinaBELTSVILLE, Md. and SHANGHAI, June 16, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, and Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical...

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. “We have had a highly productive and collaborative engagement with the FDA’s Center for Biologics Evaluation and Research (CBER)...

ZUG, Switzerland, June 16, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. “Pharvaris embraced the opportunity to engage in scientific exchange with the HAE thought leader community during EAACI as we presented data supporting the differentiated profile of deucrictibant for the prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks,” said Berndt Modig, Chief Executive Officer of Pharvaris. “Building...

Announcement marks the third phase of USD 100 million share buyback program  Dubai, June 16, 2025: VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), announces that it will shortly commence the third phase of its previously announced share buyback program with respect to the Company’s American Depositary Shares (“ADSs”). This third phase of the buyback will be in the amount of up to USD 35 million.  The third phase of the share buyback program is being launched after the successful completion of the second phase on May 21, 2025. Cumulatively, the two earlier phases of the program have resulted in the repurchase of 1.43 million ADSs at an average repurchase price of USD 45.59 per ADS. VEON had announced a share buyback program of up to USD 100 million on August 1, 2024.  The Company continues to believe that...

MIAMI BEACH, Fla., June 16, 2025 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced the voluntary prepayment of $10.0 million of its outstanding term loan debt using cash on hand, following the successful completion of its offering of 3,634,000 shares of common stock, which generated net proceeds, after estimated expenses, of approximately $13.8 million. The Company noted that with this financing and assuming no significant changes in the current macroeconomic environment, it does not anticipate the need for additional material capital raises this year. Commenting on the announcement, Yogi Jashnani, Chief Executive Officer, stated: “On the heels of our successful offering of common stock, we are pleased to apply a substantial portion...

TORONTO, June 16, 2025 (GLOBE NEWSWIRE) — Blue Moon Metals Inc. (“Blue Moon” or the “Company”) (TSXV: MOON; OTCQX: BMOOF), is pleased to announce that the company has commenced underground construction on the Nussir Mine completing the first blast on the access portal on June 12, 2025; ahead of schedule. Nussir’s mining contractor, Leonhard Nilsen & Sonner AS (“LNS”) will extend the decline approximately 2,500 meters providing a platform for further underground exploration. The exploration work to be completed over the next year will provide key engineering inputs and lead to a final investment decision in 2026. Christian Kargl-Simard, Blue Moon’s CEO states: “This key milestone marks the start of the next chapter in the exciting Nussir story and brings us one step closer to putting this important critical metals mine into...